This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Multiple companies are pursuing mRNA-based medicines that harness the body's protein-making machinery to transform lab-synthesized nucleotides into cancer-associated antigens, in the case of vaccines, or immune-stimulating molecules, in the case of therapeutics. Several candidates from BioNTech and Moderna have shown promise in early-stage testing.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
Published OnlineFirst August 13, 2019
doi: 10.1158/2159-8290.CD-ND2019-009
RNA Technologies Expand Tool Kit for Cancer Immunotherapy
Jump to section
Advertisement